Gupta Aniket, Chalotra Rishabh, Singh Randhir
Department of Pharmacology, Central University of Punjab, Bathinda, India.
Curr Diabetes Rev. 2025 Jun 16. doi: 10.2174/0115733998367395250515130758.
Preclinical Evaluation of Fisetin in the Management of Diabetic Foot Ulcer in Wistar Rats.
Diabetic foot ulcer (DFU) is a complication of diabetes mellitus, often leading to non-traumatic amputations and significantly impacting patient morbidity. Globally, the prevalence of DFU ranges from 9.1 to 26.1 million annually. A 2022 meta-analysis revealed that 6.3% of diabetic adults (33 million) are affected by DFUs. The current treatments primarily focus on topical treatments, neglecting the underlying metabolic conditions.
To investigate the wound healing efficacy of the phytoconstituent fisetin, administered orally, in managing DFU in diabetic neuropathic Wistar rats.
This study investigates the therapeutic potential of a phytoconstituent fisetin, in the management of wound healing in STZ-NAD induced diabetic animal model with surgically induced wounds after indication of neuropathy. Fisetin was administered orally at doses of 5, 10, and 15 mg/kg for 30 days following the induction of foot ulcers, Various parameters were measured, including blood glucose levels, HbA1c, lipid profile, pro-inflammatory cytokines, antioxidant activity, MDA, and histopathological analysis of wound healing.
Fisetin, particularly at 15 mg/kg, significantly modulates blood glucose level, HbA1c, lipid profile, and pro-inflammatory cytokines, further enhancing antioxidant activity, while reducing MDA, indicating a reduction in oxidative stress. Histopathological analysis demonstrated enhanced wound healing by increased fibroblast proliferation and collagen formation, as well as restoration of the epithelial layer. Fisetin also exhibited potential in enhancing re-epithelization, enhancing pro-angiogenic markers, diminishing inflammation, and reducing wound size.
Fisetin demonstrates promising potential in managing DFU by modulating metabolic conditions, reducing blood glucose, oxidative stress, and inflammation, and promoting wound healing. Future studies should focus on unraveling the detailed molecular pathways involved in fisetin's action, along with clinical trials to validate its efficacy in DFU patients.
对漆黄素治疗Wistar大鼠糖尿病足溃疡进行临床前评估。
糖尿病足溃疡（DFU）是糖尿病的一种并发症，常导致非创伤性截肢，对患者发病率有重大影响。全球范围内，DFU的年患病率在910万至2610万之间。2022年的一项荟萃分析显示，6.3%的成年糖尿病患者（3300万）受DFU影响。目前的治疗主要集中在局部治疗，而忽视了潜在的代谢状况。
研究口服植物成分漆黄素对糖尿病性神经病变Wistar大鼠DFU的伤口愈合疗效。
本研究调查了植物成分漆黄素在链脲佐菌素-烟酰胺诱导的糖尿病动物模型中，在出现神经病变迹象后通过手术造成伤口的情况下，对伤口愈合的治疗潜力。在足部溃疡诱导后，以5、10和15mg/kg的剂量口服给予漆黄素30天，测量了各种参数，包括血糖水平、糖化血红蛋白、血脂谱（血脂）、促炎细胞因子、抗氧化活性、丙二醛（MDA）以及伤口愈合的组织病理学分析。
漆黄素，特别是15mg/kg剂量时，能显著调节血糖水平、糖化血红蛋白、血脂谱和促炎细胞因子，进一步增强抗氧化活性，同时降低MDA，表明氧化应激减少。组织病理学分析显示，成纤维细胞增殖和胶原蛋白形成增加，上皮层恢复，伤口愈合得到增强。漆黄素在促进再上皮化、增强促血管生成标志物、减轻炎症和缩小伤口大小方面也表现出潜力。
漆黄素通过调节代谢状况、降低血糖、氧化应激和炎症以及促进伤口愈合，在治疗DFU方面显示出有前景的潜力。未来的研究应集中于阐明漆黄素作用所涉及的详细分子途径，以及进行临床试验以验证其对DFU患者的疗效。
